Herein, we determined whether the plasma levels of NfL and total tau (T-tau, another marker of axonal damage and neuronal degeneration), as well of GFAP, were altered in COVID-19 patients without major neurological manifestations, as compared with non-infected and neurologically healthy controls. The gene discussed is MAPT; the disease is COVID-19.